中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 10
Oct.  2024
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(10): 2034-2041

Efficacy and safety of camrelizumab monoclonal antibody combined with molecular-targeted therapy in elderly patients with advanced hepatocellular carcinoma

DOI: 10.12449/JCH241017
  • 1.

    Department of Oncology and Interventional Radiology，Beijing Ditan Hospital，Capital Medical University，Beijing 100015，China

  • 2a.

    Department of Infectious Diseases，The Second Affiliated Hospital of Xi’an Jiaotong University Xi’an 710004，China

  • 2b.

    Department of Gastroenterology，The Second Affiliated Hospital of Xi’an Jiaotong University，Xi’an 710004，China

  • 3.

    Fourth Department of Liver Diseases，Xi’an Eighth Hospital，Xi’an 710061，China

  • 4.

    Department of Infectious Diseases，The Second Affiliated Hospital of Air Force Medical University，Xi’an 710038，China

  • 5.

    Department of Hepatobiliary Surgery，Shaanxi Provincial People’s Hospital，Xi’an 710068，China

  • 6.

    Department of Infectious Diseases，Shandong Provincial Hospital，Jinan 250021，China

  • 7.

    Department of Medical Oncology，The First Affiliated Hospital of Xi’an Jiaotong University，Xi’an 710061，China

  • 8.

    Department of Hematology，Rheumatology and Immunology，The First People’s Hospital of Xianyang，Xianyang，Shaanxi 721000，China

  • 9.

    Department of Infectious Diseases，Nanjing Drum Tower Hospital，Nanjing 210008，China

Research funding:

National Natural Science Foundation of China (82170626);

Natural Science Foundation of Shaanxi Province (2022SF-451);

Capital Health Development Research Special Project (2024-2-2176)

More Information
  • Corresponding author: GUO Jiang， guojiang7606@ccmu.edu.cn （ORCID： 0000-0001-8297-5458）; GAO Ning， gaohuining1@163.com （ORCID： 0000-0003-1018-3990）
  • Received Date: 2024-01-22
  • Accepted Date: 2024-04-29
  • Published Date: 2024-10-25
    Abstract
  •   Objective  To investigate the efficacy and safety of camrelizumab monoclonal antibody combined with molecular-targeted therapy in elderly patients with unresectable or advanced hepatocellular carcinoma （HCC）.  Methods  A retrospective analysis was performed for the patients with unresectable/advanced HCC who attended six hospitals from January 1， 2019 to March 31， 2021， and all patients received camrelizumab monoclonal antibody treatment， among whom 84.8% also received targeted therapy. According to the age of the patients， they were divided into elderly group （≥65 years） and non-elderly group （<65 years）. The two groups were assessed in terms of overall survival （OS）， progression-free survival （PFS）， objective response rate （ORR）， disease control rate （DCR）， and immune-related adverse events （irAE）. The chi-square test or the Fisher’s exact test was used for comparison of categorical data between groups； the independent samples t-test was used for comparison of normally distributed continuous data， and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups. The Kaplan-Meier method was used for survival analysis， and the log-rank test was used for comparison of survival curves. Univariate and multivariate Cox proportional hazards regression analyses were used to determine the independent influencing factors for PFS and DCR at 6 months.  Results  A total of 99 HCC patients were enrolled， with 27 in the elderly group and 72 in the non-elderly group. The elderly group had an OS rate of 67.8%， an ORR of 44.4%， and a DCR of 74.1% at 12 months and a median PFS of 6.4 （95% confidence interval ［CI］： 3.0‍ ‍—‍ ‍12.4） months， with no significant differences compared with the non-elderly group （all P>0.05）. The median OS was unavailable for the elderly group， while the non-elderly group had an OS of 18.9 （95%CI： 13.0‍ ‍—‍ ‍24.8） months； there was no significant difference between the two groups （P=0.485）. The univariate and multivariate Cox regression analyses showed that major vascular invasion （MVI） was an independent risk factor for PFS （hazard ratio ［HR］=2.603， 95%CI： 1.136‍ ‍—‍ ‍5.964， P=0.024） and DCR （HR=3.963， 95%CI： 1.671‍ ‍—‍ ‍9.397， P=0.002） at 6 months， while age， sex， etiology of HBV infection， presence of extrahepatic metastasis， Child-Pugh class B， and alpha-fetoprotein>400 ng/mL were not associated with PFS or DCR at 6 months. For the elderly group， the incidence rates of any irAE and grade 3/4 irAE were 51.9% and 25.9%， respectively， with no significant differences compared with the non-elderly group （P>0.05）， and skin disease was the most common irAE in both groups （39.4%）.  Conclusion  Camrelizumab monoclonal antibody combined with molecular-targeted therapy has similar efficacy and safety in patients with unresectable/advanced HCC aged ≥65 years and those aged <65 years. MVI is associated with suboptimal response to immunotherapy and poor prognosis.

     

    • FullText(HTML)
  • loading
    • References(23)
  • [1]
    YANG JD, HAINAUT P, GORES GJ, et al. A global view of hepatocellular carcinoma: Trends, risk, prevention and management[J]. Nat Rev Gastroenterol Hepatol, 2019, 16( 10): 589- 604. DOI: 10.1038/s41575-019-0186-y.
    [2]
    RUMGAY H, ARNOLD M, FERLAY J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040[J]. J Hepatol, 2022, 77( 6): 1598- 1606. DOI: 10.1016/j.jhep.2022.08.021.
    [3]
    SMITH BD, SMITH GL, HURRIA A, et al. Future of cancer incidence in the United States: Burdens upon an aging, changing nation[J]. J Clin Oncol, 2009, 27( 17): 2758- 2765. DOI: 10.1200/JCO.2008.20.8983.
    [4]
    LLOVET JM, KELLEY RK, VILLANUEVA A, et al. Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2021, 7: 6. DOI: 10.1038/s41572-020-00240-3.
    [5]
    LIU JH, CHEN ZC, LI YQ, et al. PD-1/PD-L1 checkpoint inhibitors in tumor immunotherapy[J]. Front Pharmacol, 2021, 12: 731798. DOI: 10.3389/fphar.2021.731798.
    [6]
    RAO Q, LI M, XU W, et al. Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: A systematic review and meta-analysis[J]. Hepatol Int, 2020, 14( 5): 765- 775. DOI: 10.1007/s12072-020-10064-8.
    [7]
    WANG Y, JIANG M, ZHU JJ, et al. The safety and efficacy of lenvatinib combined with immune checkpoint inhibitors therapy for advanced hepatocellular carcinoma[J]. Biomedecine Pharmacother, 2020, 132: 110797. DOI: 10.1016/j.biopha.2020.110797.
    [8]
    FINN RS, IKEDA M, ZHU AX, et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma[J]. J Clin Oncol, 2020, 38( 26): 2960- 2970. DOI: 10.1200/JCO.20.00808.
    [9]
    OMATA M, CHENG AL, KOKUDO N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: A 2017 update[J]. Hepatol Int, 2017, 11( 4): 317- 370. DOI: 10.1007/s12072-017-9799-9.
    [10]
    LI T, GUO J, LIU YS, et al. Effectiveness and tolerability of camrelizumab combined with molecular targeted therapy for patients with unresectable or advanced HCC[J]. Cancer Immunol Immunother, 2023, 72( 7): 2137- 2149. DOI: 10.1007/s00262-023-03404-8.
    [11]
    LLOVET JM, LENCIONI R. mRECIST for HCC: Performance and novel refinements[J]. J Hepatol, 2020, 72( 2): 288- 306. DOI: 10.1016/j.jhep.2019.09.026.
    [12]
    MEI KM, QIN SK, CHEN ZD, et al. Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: Cohort A report in a multicenter phase Ib/II trial[J]. J Immunother Cancer, 2021, 9( 3): e002191. DOI: 10.1136/jitc-2020-002191.
    [13]
    CAI JQ, ZHANG BL, BI XY. Comprehensive treatment strategy for hepatocellular carcinoma based on surgical treatment in the era of targeted therapy and immunotherapy[J]. Chin J Dig Surg, 2023, 22( 2): 181- 186. DOI: 10.3760/cma.j.cn115610-20221130-0071.

    蔡建强, 张搏伦, 毕新宇. 靶向联合免疫治疗时代以外科为主的肝细胞癌综合治疗策略[J]. 中华消化外科杂志, 2023, 22( 2): 181- 186. DOI: 10.3760/cma.j.cn115610-20221130-00719.
    [14]
    LI H, QIN SK, LIU Y, et al. Camrelizumab combined with FOLFOX4 regimen as first-line therapy for advanced hepatocellular carcinomas: A sub-cohort of a multicenter phase ib/II study[J]. Drug Des Devel Ther, 2021, 15: 1873- 1882. DOI: 10.2147/DDDT.S304857.
    [15]
    YUAN GS, CHENG X, LI Q, et al. Safety and efficacy of camrelizumab combined with apatinib for advanced hepatocellular carcinoma with portal vein tumor Thrombus: A multicenter retrospective study[J]. Onco Targets Ther, 2020, 13: 12683- 12693. DOI: 10.2147/OTT.S286169.
    [16]
    QIN SK, REN ZG, MENG ZQ, et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: A multicentre, open-label, parallel-group, randomised, phase 2 trial[J]. Lancet Oncol, 2020, 21( 4): 571- 580. DOI: 10.1016/S1470-2045(20)30011-5.
    [17]
    XU JM, SHEN J, GU SZ, et al. Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma(RESCUE): A nonrandomized, open-label, phase II trial[J]. Clin Cancer Res, 2021, 27( 4): 1003- 1011. DOI: 10.1158/1078-0432.CCR-20-2571.
    [18]
    VITHAYATHIL M, D’ALESSIO A, FULGENZI CAM, et al. Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma[J]. Liver Int, 2022, 42( 11): 2538- 2547. DOI: 10.1111/liv.15405.
    [19]
    TADA T, KUMADA T, HIRAOKA A, et al. Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis[J]. Cancer Med, 2022, 11( 20): 3796- 3808. DOI: 10.1002/cam4.4763.
    [20]
    BORZIO M, DIONIGI E, VITALE A, et al. Management and prognosis of hepatocellular carcinoma in the elderly: Results of an in-field multicenter cohort study[J]. Liver Int, 2017, 37( 8): 1184- 1192. DOI: 10.1111/liv.13392.
    [21]
    GUO H, WU T, LU Q, et al. Hepatocellular carcinoma in elderly: Clinical characteristics, treatments and outcomes compared with younger adults[J]. PLoS One, 2017, 12( 9): e0184160. DOI: 10.1371/journal.pone.0184160.
    [22]
    DELIGIORGI MV, TRAFALIS DT. Reversible primary adrenal insufficiency related to anti-programmed cell-death 1 protein active immunotherapy: Insight into an unforeseen outcome of a rare immune-related adverse event[J]. Int Immunopharmacol, 2020, 89( Pt B): 107050. DOI: 10.1016/j.intimp.2020.107050.
    [23]
    ZHANG Y, ZHANG X, LI W, et al. Biomarkers and risk factors for the early prediction of immune-related adverse events: a review[J]. Hum Vaccin Immunother, 2022, 18( 1): 2018894. DOI: 10.1080/21645515.2021.2018894.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(5)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (131) PDF downloads(12) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return